Back to results

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Primary Purpose

Tuberculosis

Status

Completed

Phase

Phase 1

Locations

Finland

Study Type

Interventional

Intervention

AERAS-404

Placebo

About this trial

This is an interventional prevention trial for Tuberculosis focused on measuring BCG Vaccinated, HIV Negative

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Has completed written informed consent
Is male or female
Is age 18 through 45 years on Study Day 0
Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar
Has general good health, confirmed by medical history and physical examination
Has a Body Mass Index (BMI) between 19 and 33
Agrees to complete a follow-up period of 182 days as required by the protocol
Females: Agrees to avoid pregnancy from 28 days prior to Study Day 0 through the follow-up period of 182 days. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses) must agree to avoid pregnancy using an acceptable method
Agrees to avoid elective surgery for the duration of the study
Agrees to stay in contact with the investigative site for the study duration
Completed simultaneous enrollment in Aeras Vaccine Development Registry protocol

Exclusion Criteria:

Acute illness on Study Day 0
Axillary temperature >=37.5 degrees Celsius on Study Day 0
Evidence of significant active infection
Used immunosuppressive medication within 42 days before Study Day 0
Received immunoglobulin or blood products within 42 days before Study Day 0
Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0
Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study, or any other standard vaccine within 42 days before Study Day 0
Current chronic drug therapy including hormone replacement such as thyroxin, insulin
History or laboratory evidence of past, present or future possible immunodeficiency state which include any laboratory indication of HIV infection
History of allergic disease or reactions, including eczema
Previous medical history that may compromise safety of the subject in the study
Evidence of new acute illness that may compromise the safety of subject in the study
Evidence of chronic hepatitis
Inability to discontinue daily medications except contraceptives during study period
History of alcohol or drug abuse within past 2 years
Tobacco or cannabis smoking three or more days per week
Positive urine test for illicit drugs
History or evidence of any systemic disease on physical examination
History or evidence of active tuberculosis
Shared a residence within the last year with a individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
All females: Positive urine pregnancy test during screening
Abnormal (per local laboratory parameters) chemistry and hematology parameters
QuantiFERON®-TB Gold evidence of Mtb infection
Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0

Sites / Locations

University of Tampere Vaccine Research Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Arm Label

Cohort 1 AERAS-404

Cohort 2 AERAS-404

Cohort 3 AERAS-404

Cohort 4 AERAS-404

Cohort 5 AERAS-404

Arm Description

H4 Antigen at 5 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

H4 Antigen at 15 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

H4 Antigen at 50 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

H4 Antigen at 150 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer 2 doses at Study days 0 and 56

Outcomes

Primary Outcome Measures

Safety profile of two injections of AERAS 404 at different dose levels of antigen and adjuvant.

Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study. Solicited and unsolicited adverse events are captured 28 days post each vaccination. The safety profile of AERAS-404 will be summarized by treatment regimen. The number (percentage) of subjects with adverse events will be summarized by MedDRA system organ class (SOC), and preferred term (PT). Additional summaries will present the number (percentage) of subjects with adverse events by severity and by relationship to study vaccine.

Secondary Outcome Measures

Immunogenicity of two injections of AERAS 404 at different dose levels of antigen and adjuvant.

Intracellular cytokine staining will be used to assess immunogenicity. Immune response based on percentages of CD4+ and CD8+ T cells that produced one, two, or three cytokines (IFN-γ, TNF-α, and/or IL-2) in response to stimulation with one of 2 antigenic peptide pools (Ag85B and TB10.4) derived from and representing the entire amino acid sequences of the mycobacterial antigens Ag85B and TB10.4, respectively.

Full Information

NCT ID

NCT02074956

First Posted

February 27, 2014

Last Updated

March 14, 2014

Sponsor

Aeras

Collaborators

Statens Serum Institut

1. Study Identification

Unique Protocol Identification Number

NCT02074956

Brief Title

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Official Title

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as Different IC31 Adjuvant Amounts With Different AERAS-404 (HyVac4) Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Study Type

Interventional

2. Study Status

Record Verification Date

March 2014

Overall Recruitment Status

Completed

Study Start Date

May 2008 (undefined)

Primary Completion Date

October 2009 (Actual)

Study Completion Date

October 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Aeras

Collaborators

Statens Serum Institut

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This Phase I study will be conducted as a randomized, double-blind, dose-escalation study in five groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis infection. Since BCG-vaccinated individuals are the target population for which AERAS 404 might be indicated, AERAS 404 will be administered to individuals already vaccinated with BCG

Detailed Description

Sixty subjects will be sequentially enrolled into one of five study groups (i.e., Group 1, Group 2, Group 3, Group 4, or Group 5) with 10 subjects per group in Groups 1-4 and 20 subjects in Group 5. Within each study group, subjects will be randomized to a treatment assignment of either AERAS-404 or placebo control at a ratio of 4:1 (Groups 1-4) or two different dose amounts of AERAS-404 or placebo control at a ratio of 9:9:2 (Group 5) administered by intramuscular injection on Study Day 0 and Study Day 56. The principal investigator will determine an appropriate interval between the vaccinations such that the entire group is not dosed at the same time. All subjects will receive the same treatment on Study Day 0 as they receive on Study Day 56. All subjects will be followed for safety and immunogenicity evaluations for 182 days. A total of eleven clinic visits are planned (excluding screening) for all subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Tuberculosis

Keywords

BCG Vaccinated, HIV Negative

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

60 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Cohort 1 AERAS-404

Arm Type

Experimental

Arm Description

H4 Antigen at 5 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

Arm Title

Cohort 2 AERAS-404

Arm Type

Experimental

Arm Description

H4 Antigen at 15 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

Arm Title

Cohort 3 AERAS-404

Arm Type

Experimental

Arm Description

H4 Antigen at 50 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

Arm Title

Cohort 4 AERAS-404

Arm Type

Experimental

Arm Description

H4 Antigen at 150 ug IC31 Adjuvant 500 nmol 2 doses at Study days 0 and 56

Arm Title

Cohort 5 AERAS-404

Arm Type

Experimental

Arm Description

H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer 2 doses at Study days 0 and 56

Intervention Type

Biological

Intervention Name(s)

AERAS-404

Other Intervention Name(s)

Intervention Description

AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention Type

Biological

Intervention Name(s)

Placebo

Other Intervention Name(s)

Sterile Buffer

Intervention Description

Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.

Primary Outcome Measure Information:

Title

Safety profile of two injections of AERAS 404 at different dose levels of antigen and adjuvant.

Description

Time Frame

Total duration of study follow up for all subjects is 182 days.

Secondary Outcome Measure Information:

Title

Immunogenicity of two injections of AERAS 404 at different dose levels of antigen and adjuvant.

Description

Time Frame

Immunogenicity was evaluated from blood collected at Study Days 0, 7, 14, 28, 56, 63, 70, 84, and 182. For all subjects, a QuantiFERON-TB Gold test was performed during screening and at Study Day 182

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

45 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Has completed written informed consent Is male or female Is age 18 through 45 years on Study Day 0 Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar Has general good health, confirmed by medical history and physical examination Has a Body Mass Index (BMI) between 19 and 33 Agrees to complete a follow-up period of 182 days as required by the protocol Females: Agrees to avoid pregnancy from 28 days prior to Study Day 0 through the follow-up period of 182 days. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses) must agree to avoid pregnancy using an acceptable method Agrees to avoid elective surgery for the duration of the study Agrees to stay in contact with the investigative site for the study duration Completed simultaneous enrollment in Aeras Vaccine Development Registry protocol Exclusion Criteria: Acute illness on Study Day 0 Axillary temperature >=37.5 degrees Celsius on Study Day 0 Evidence of significant active infection Used immunosuppressive medication within 42 days before Study Day 0 Received immunoglobulin or blood products within 42 days before Study Day 0 Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0 Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study, or any other standard vaccine within 42 days before Study Day 0 Current chronic drug therapy including hormone replacement such as thyroxin, insulin History or laboratory evidence of past, present or future possible immunodeficiency state which include any laboratory indication of HIV infection History of allergic disease or reactions, including eczema Previous medical history that may compromise safety of the subject in the study Evidence of new acute illness that may compromise the safety of subject in the study Evidence of chronic hepatitis Inability to discontinue daily medications except contraceptives during study period History of alcohol or drug abuse within past 2 years Tobacco or cannabis smoking three or more days per week Positive urine test for illicit drugs History or evidence of any systemic disease on physical examination History or evidence of active tuberculosis Shared a residence within the last year with a individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis All females: Positive urine pregnancy test during screening Abnormal (per local laboratory parameters) chemistry and hematology parameters QuantiFERON®-TB Gold evidence of Mtb infection Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Zhongkai Shi, MD

Organizational Affiliation

Aeras

Official's Role

Study Director

First Name & Middle Initial & Last Name & Degree

Timo Vesikari, MD

Organizational Affiliation

University of Tampere Vaccine Research Clinic

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of Tampere Vaccine Research Clinic

City

Biokatu

State/Province

Tampere

ZIP/Postal Code

33100

Country

Finland

12. IPD Sharing Statement

Citations:

PubMed Identifier

28216183

Citation

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff THM, Andersson J, Brighenti S. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine. 2017 Mar 14;35(12):1652-1661. doi: 10.1016/j.vaccine.2017.01.055. Epub 2017 Feb 17.

Results Reference

derived

Learn more about this trial

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

We'll reach out to this number within 24 hrs